Nektar Therapeutics (NKTR) Total Non-Current Liabilities (2010 - 2026)

Nektar Therapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $178.6 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 24.24% year-over-year to $178.6 million in Q1 2026; TTM through Mar 2026 was $178.6 million, a 24.24% decrease from a year earlier, with the FY2025 full-year figure at $181.9 million, down 22.86% from the prior year.
• Total Non-Current Liabilities retreated to $178.6 million in Q1 2026 per NKTR's latest filing, from $181.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $416.2 million in Q1 2022 and bottomed at $178.6 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $262.4 million (2023), against an average of $277.2 million.
• Across the five-year window, Total Non-Current Liabilities declined 9.01% in 2022 and decreased 27.17% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $336.4 million in 2022, then slipped by 22.0% to $262.4 million in 2023, then decreased by 10.11% to $235.9 million in 2024, then retreated by 22.86% to $181.9 million in 2025, then fell by 1.84% to $178.6 million in 2026.
• Per Business Quant, the three latest NKTR Total Non-Current Liabilities figures stand at $178.6 million (Q1 2026), $181.9 million (Q4 2025), and $211.2 million (Q3 2025).